EPCAM and breast cancer: CTCs in blood samples from 107 BC patients were evaluated using immunomagnetic depletion and multi‐marker immunofluorescence (EpCAM, E‐cadherin, MCAM, cell surface vimentin, CD31, CD45), followed by single‐cell transcriptomics.